Healthcare Industry News: Beckman Coulter
News Release - April 16, 2007
Beckman Coulter Commercializes First Automated Inhibin A AssaySuccessful Transfer of DSL ELISA Method
FULLERTON, Calif., April 16 (HSMN NewsFeed) -- Beckman Coulter, Inc. (NYSE: BEC ), the leading manufacturer of diagnostics instruments in the U.S., has introduced Access® Inhibin A -- the first automated assay for the quantitative determination of dimeric inhibin A levels in human serum and plasma. Inhibin A is used as an aid in the diagnosis and monitoring of various reproductive hormonal disorders. Through the acquisition of Diagnostic System Laboratories, Inc. (DSL), Beckman Coulter has an exclusive license to manufacture and market the assay.
"Our company has a proven track record of successful, strategic transactions that result in the introduction and commercialization of innovative new products. Inhibin A is just the first of several high-value, exclusive or semi-exclusive assays that we expect to develop as a result of our acquisition of DSL," said Richard Creager, corporate vice president, immunoassay business center. "Our ability to take DSL's ELISA methods and turn them into automated assays illustrates our key strategy of leveraging our unique strengths to simplify and automate laboratory processes to improve patient health and reduce the cost of care."
By automating Inhibin A, Beckman Coulter enables laboratories to run a common panel of reproductive tests on one analyzer from one patient sample. Published reports also indicate the utility of Inhibin A for monitoring ovarian function. The test is available on any of Beckman Coulter's family of immunoassay systems, including the Access 2 and the UniCel® DxI 800 Access immunoassay systems.
In addition to a complete panel of reproductive assays, Beckman Coulter immunoassay systems offer highly accurate and sensitive tests for a variety of disease states, including cardiac, cancer, anemia, thyroid function, infectious disease and bone metabolism.
About Beckman Coulter, Inc.
Based in Fullerton, California, Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue consisting of supplies, test kits, service and operating-type lease payments represents more than 75 percent of the company's 2006 annual revenue of $2.53 billion. For more information, visit www.beckmancoulter.com.
Source: Beckman Coulter
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.